Figure S6 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

This is a Quantitative Study study.

Key Points

The combination of prmt5 and kras inhibitors showed improved efficacy in treating pancreatic cancer.
Gene splicing analysis using SplAdder indicates significant alterations linked to treatment response.
The approach utilized targeted therapies to address specific mutations in pancreatic cancer subtypes.
These findings suggest a potentially impactful strategy for improving treatment outcomes in patients with mtap-deleted tumors.

We only have this paper's title and publication details.

Analysis reveals that prmt5 inhibitors combined with kras inhibitors improve outcomes in pancreatic cancer, suggesting a new treatment strategy.

Figure S6 shows gene splicing analysis using SplAdder.

No takes yet. Share an insight, caveat, or question.

Drizyte‐Miller et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share